RecruitingPhase 1NCT06555744
A Study of ZW191 in Participants With Solid Tumors
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors
Sponsor
Zymeworks BC Inc.
Enrollment
145 participants
Start Date
Oct 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease.
- Measurable disease per RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- Adequate cardiac function: Cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram (ECHO) or multigated acquisition scan (MUGA).
- Other adequate organ function.
Exclusion Criteria4
- Known additional malignancy that is progressing or requires active treatment or may interfere with study endpoints.
- Has received prior Topoisomerase I inhibitor(TOPO1i) antibody drug conjugate treatment, regardless of washout period.
- Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease.
- Severe chronic or active infections (including known active SARS-CoV-2 infection) requiring systemic therapy, including antibacterial, antifungal, or antiviral therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGZW191
Administered intravenously
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06555744
Related Trials
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT07435038
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT0600424538 locations
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT073495379 locations
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
NCT066052221 location
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
NCT067990656 locations